Modélisation toxicocinétique d’un mélange de composés organiques volatils dans l’eau potable by Kaveh, Nazanin
 Université de Montréal 
 
 
 
 
Modélisation toxicocinétique d’un mélange de composés 
organiques volatils dans l’eau potable 
 
 
 
  
Par 
 
Nazanin Kaveh 
 
 
 
 
 
 
 
Département de santé environnementale et santé au travail  
Faculté de médecine 
 
 
 
 
 
 
Mémoire présenté à la Faculté des études supérieures en vue 
de l’obtention du grade de Maîtrise ès Sciences (M.Sc.) 
                           en santé environnementale et santé au travail 
 
 
 
 
Avril 2012 
 
© Nazanin Kaveh, 2012 
 
 
  
ii 
Université de Montréal 
 
Faculté des études supérieures 
 
 
 
 
Ce mémoire intitulé : 
 
Modélisation toxicocinétique d’un mélange de composés 
organiques volatils dans l’eau potable 
 
 
 
 
 
Présenté par:  
 
Nazanin Kaveh 
 
 
 
 
 
 
A été évalué par un jury composé des personnes suivantes: 
 
 
Professeur Michel Gérin, président rapporteur 
 
Professeur Kannan Krishnan, directeur de recherche 
 
Professeure Michèle Bouchard, membre du jury 
 
 
 
 
 
 
Mémoire accepté le……………….. 
 
 
 
  
iii
RÉSUMÉ 
 
L'évaluation des risques de l'exposition aux mélanges de produits chimiques 
par voies multiples peut être améliorée par une compréhension de la 
variation de la dose interne due à l’interaction entre les produits. Les modèles 
pharmacocinétiques à base physiologique (PBPK) sont des outils éprouvés pour 
prédire l'ampleur de ces variations dans différents scénarios.  
Dans cette étude, quatre composés organiques volatils (COV) (toluène, n-
hexane, cyclohexane et isooctane) ont été choisis pour représenter des produits 
pétroliers (essence) pouvant contaminer l'eau potable. Premièrement, les 
modèles PBPK ont simulé l'exposition à un seul COV par une voie (inhalation ou 
gavage). Ensuite, ces modèles ont été interconnectés pour simuler l'exposition à 
un mélange par voies multiples. Les modèles ont été validés avec des données 
in vivo chez des rats Sprague-Dawley (n=5) exposés par inhalation (50 ppm ; 
toluène, hexane, et 300 ppm ; cyclohexane, isooctane; 2-h) ou par gavage (8,3; 
5,5; 27,9 et 41,27 mg/kg pour le toluène, l’hexane, le cyclohexane et l’isooctane, 
respectivement). Des doses similaires ont été utilisées pour l'exposition au 
mélange par voies multiples. Les AUC (mg/L x min) pour le toluène, l'hexane, le 
cyclohexane et l'isooctane étaient respectivement de 157,25; 18,77; 159,58 et 
176,54 pour les données expérimentales, et 121,73; 21,91; 19,55 et 170,54 pour 
les modèles PBPK. Les résultats des modèles PBPK et les données in vivo 
(simple COV par voies multiples vs. mélange par voies multiples) ont montré des 
interactions entre les COVs dans le cas de l'exposition au mélange par voies 
multiples. Cette étude démontre l'efficacité des modèles PBPK pour simuler 
l'exposition aux mélanges de COV par voies multiples. 
 
Mots clé : 
Analyse de risque, Mélange, Voies multiples, PBPK
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ABSTRACT 
 
Risk assessment focusing on exposure to mixtures by multiple routes can be 
improved with an understanding of the changes in internal doses due to 
interaction among chemicals. Physiologically based pharmacokinetic (PBPK) 
models are proven tools to predict the magnitude of interaction in various 
scenarios. In this study, four volatile organic compounds (VOCs) (toluene, n-
hexane, cyclohexane and isooctane) were chosen to represent petroleum 
products that could contaminate the drinking water (e.g. gasoline). PBPK models 
were used first to simulate exposure to a single chemical by a single route 
(inhalation, gavage) and simulate exposure to a mixture by multiple routes. PBPK 
models were validated by comparing simulations with in vivo data. These data 
were collected from groups of male Sprague-Dawley rats (n=5) exposed by 
inhalation (50 ppm of toluene, hexane; 300 ppm of cyclohexane and isooctane; 
2-hr) or gavage (8.3, 5.5, 27.9, and 41.27 mg/kg, respectively, for toluene, 
hexane, cyclohexane and isooctane). For exposure to the mixture by multiple 
routes, same doses were used. The AUCs (mg/L x min) based on experimental 
data were 157.25, 18.77, 159.58 and 176.54 and the AUCs of the PBPKs model 
were 121.73, 21.91, 19.55 and 170.54, respectively, for toluene, hexane, 
cyclohexane and isooctane. Results from both PBPK models and in vivo data 
(single VOC, multiple routes vs. mixture, multiple routes) showed interactions 
between VOCs in the case of exposure to the mixture by multiple routes. This 
study demonstrated that the PBPK model is an effective tool to simulate 
exposure to mixtures of VOCs by multiple routes. 
 
Keywords: 
Risk assessment, Mixture, Multiple routes, PBPK 
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‘All people, whatever their stage of development and their social and economic 
conditions, have the right to have access to an adequate supply of safe drinking water’ 
WHO 
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Canada is the home of one of the biggest natural resources on earth, namely 
water. About seven per cent of the world’s fresh water is in Canada. The St 
Lawrence River and the Great Lakes in the east, the Mackenzie River in the 
north-west are important to the Canadian economy and supply drinking water for 
millions of people. However, these resources are susceptible to contamination by 
different sources such as human activities, animal waste, industrial activities (i.e., 
pesticides and fuel leakage). Therefore, the cleaning up of contaminated rivers 
(e.g., the St. Lawrence) and lakes (e.g., the Great Lakes) and protecting people 
by developing guidelines for drinking water quality (i.e., pollution prevention, 
managing toxic chemicals) should continue to be priorities in Canada 
(Environment Canada).  
 
1.1. Development of guideline values for drinking water  
 
To date, guideline values for drinking water are developed considering only oral 
route exposure by Health Canada and the United States Environmental 
Protection Agency (U.S. EPA) (Krishnan and Carrier, 2008). In this regard, the 
guideline value for a substance in water is calculated as the ratio between the 
maximal allowable amount consumed (i.e., Tolerable Daily Intake by Health 
Canada (TDI; mg/kg/day) or Reference Dose by U.S. EPA (RfD; mg/kg/day) x 
Body Weight (BW; kg) x Source Allocation Factor (SAF; 0.2 for each source of 
contamination: water, air, soil, food and consumer product)) and the daily water 
intake rate (1.5 L/day used by Health Canada; 2 L/day used by U.S. EPA):   
 
(TDI or RfD) x BW x SAFGuideline value = 
water intake rate
                                                      [1]      
      
However, studies as early as 1984 have shown the importance of dermal and 
inhalation routes, especially in the case of water contamination by volatile 
organic compounds (VOCs) (Brown et al., 1984; Andelman, 1985; McKone, 
1987; Weisel et al., 1996; Kim et al., 2001). Among different chemical 
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contaminants, VOCs have interested regulators because of their potential for 
multiple routes of exposure due to their ubiquitous distributions in the various 
environmental compartments (Pohl and Scinicariello, 2011). Large numbers of 
VOCs are used as additives in fuel in order to increase its burning capacity (Lee 
et al., 2002; Lin et al., 2005). Their particular physiochemical characters are low 
water solubility, high vapor pressure and low molecular weight (Liu and Zhou, 
2011). These specific characteristics of VOCs give them a marked capacity to 
transfer from fuel to air and to contaminate surface and underground water 
sources (U.S. EPA, 1990). As a result, the general population can be exposed to 
these chemicals in water supplies not only via the oral route but also through the 
dermal route by bathing, showering and by inhalation of indoor air (Mckone, 
1999). Because of its large absorptive surface area (50- 100 m2) (Deshpande, 
2005), the lungs are important routes for absorption of VOCs in ambient air. 
Brown et al. (1984) indicated that VOC absorption via skin can occur as a result 
of direct contact with water, such as showering, bathing or swimming. In addition, 
several studies demonstrated the contribution of inhalation and dermal routes to 
total internal dose of VOCs in water. For example, in 1996, Weisel and Jo 
designed a well-controlled exposure scenario (i.e., via oral, inhalation and dermal 
routes) to chloroform (CHL) and trichloroethene (TCE), in humans to evaluate the 
contribution of each exposure route to the internal dose of VOCs. Eleven 
subjects participated in a total of 25 experiments which included a 10-minute 
shower (dermal contact: CHL, 10-41 µg/l; TCE, 16-150 µg/), a 60-minute bath 
(dermal contact; T= 40ºC) and a 10-minute inhalation exposure (CHL, 10-50 µg/l; 
TCE, 28-41 µg/l) during shower. The subjects were also exposed by the oral 
route by drinking 0.5 liter of tap water (CHL, 20 µg/l; TCE, 20-40 µg/l). The CHE 
and TCE were present in the exhaled breath following inhalation exposure (0.25-
0.05 µg/l CHL and 1.0-0.1 µg/ TCE, 30-180 minute following exposure) and 
dermal exposure (0.33-0.00 µg/l CHL and 0.9-0.01 µg/l TCE, 30-180 minutes 
following exposure). However, results of breath samples taken minutes after 
ingestion of tap water, showed no trace of CHL. This indicates that CHL is totally 
metabolized through the first pass in the liver. On the other hand, TCE was found 
  
5
seconds to minutes after ingestion of water, in the exhaled breath. The authors 
indicate that this is an outcome of the low water/air partition coefficient, which 
results into rapid transfer of TCE from water to air in the oral cavity. Based on 
their observations, after oral ingestion, the absence of continued elevation of the 
VOC in the exhaled air shows that blood:air exchange in the alveolar sac has no 
importance. They concluded that the rate of metabolism of VOCs and therefore 
their potential toxicity is dependent on the exposure route. 
  
Another study by Xu and Weisel (2005) on human subjects, also demonstrated 
that the dermal route has an important effect on the absorption of VOCs such as 
CHL, 1,1-dichloropropanone (DCP) and 1,1,1-trichloropropanone (TCP) used to 
disinfect tap water. In a well-controlled dermal exposure environment, subjects 
(n=6) took baths in water (T: 38±1 ºC) with 40 µg/l of CHL (well below the 
concentration found in tap water) and 25 µg/l of DCP and TCP (higher than 
concentrations that can be found in a poorly controlled water system) for 30 
minutes. Results show that maximum breath concentration of CHL during dermal 
exposure varied between 20 to 90 percent (16-34 µg/l) of the initial concentration 
among subjects. At the same time, maximum breath concentration of detected 
DCP was as little as two percent (0.1-0.9 µg/l) whereas for TCP, it was less than 
one percent of the initial dose (0.07-0.25 µg/l).  
 
These studies suggested that traditional approaches to evaluate guidelines for 
drinking water are inadequate to account for multiple routes of exposure. 
Consequently, guideline value derivation for drinking water contaminants (DWC) 
has been improved as follows (Krishnan and Carrier, 2008): 
 
G (TDI or RfD) x BW x SAFuideline value = 
intake rate + L-eq
                                                       [2] 
                            
In the above equation, L-eq (liter equivalent) corresponds to the number of liters 
of the dermal and inhalation exposure equivalent to oral exposure. In other 
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words, L-eq is the fraction of the daily dose received by inhalation or dermal 
route relative to the dose absorbed by the oral route. The L-eq values are 
obtained on the basis of dose received via either inhalation or dermal route as 
follows: 
 
dose absorbed via inhalation route (mg) x IR (L) L-eq inhalation (L) = 
 dose absorbed via oral route (mg)
           [3] 
 
dose absorbed via dermal route (mg) x IR (L) L-eq dermal (L) = 
 dose absorbed via oral route (mg)
                    [4] 
 
IR: daily intake rate 
Therefore the total L-eq is: 
 
L-eq total (L) = L-eq inhalation (L) + L-eq dermal (L) + IR (L)                               [5] 
 
The L-eq can be calculated if the absorbed dose for the various routes can be 
estimated using human biomarkers or pharmacokinetic data (i.e., blood 
concentration, expired alveolar breath) after dermal or inhalation exposure in a 
controlled environment. However, conducting the necessary human experiments 
in order to compute the L-eq for all VOCs is not feasible (Krishnan and Carrier, 
2008). In this regard, the use of mathematical models would be practical. The 
capacity of physiologically based pharmacokinetic (PBPK) models to predict 
absorption, distribution, metabolism and excretion of VOCs has already been 
proven (Ali and Tardif, 1999). Also, these models are increasingly used in 
regulatory risk assessment processes for VOCs in drinking water. For example, 
as early as 1988, Bogen and Hall developed the PBPK model to predict the safe 
concentration of methyl chloroform (MC) in drinking water based on a no 
observed adverse effect level (NOAEL) from experimental data in rodents. In the 
same study, they also applied a PBPK model for multiple routes of exposure (i.e., 
inhalation, ingestion and dermal) to MC in humans. They concluded that the safe 
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concentration of MC in the water based on their modeling and data evaluations 
would be lower than that calculated based on the traditional method. Haddad et 
al. (2007) established a PBPK model to analyze the contribution of each route of 
exposure to the total absorbed dose and total metabolized amounts of five VOCs 
(CHL, TCE, bromodichloromethane, dibromochloromethane, bromoform). They 
developed the model to predict human exposure via single route, for individual 
chemicals in tap water. They assumed that exposure occurs in the bathroom and 
elsewhere in the house during daily activities such as drinking, bathing and 
showering. In this study, total amounts absorbed and metabolized were 
calculated by adding separate amounts for inhalation, dermal and ingestion 
routes. They concluded that dermal and inhalation (showering) exposures 
contribute as much as, or even more than, the ingestion of water in terms of total 
absorbed dose of VOCs. They also indicated that these PBPK models can be 
useful to establish guidelines for different VOCs in the water, to account for multi-
route exposures. 
 
Although previous studies on single chemicals have demonstrated the 
usefulness of PBPK models, the evaluation of possible interactions during mixed 
exposure to chemicals via multiple routes has not yet been undertaken. Human 
exposure to chemical mixtures found in the environment has been well 
documented (Newill, 1989; Saéz et Rittman, 1993; Eskenazi et al. 1999; FSA, 
2002; Wolff et al. 2008). The U.S. EPA, National Institute of Occupational Safety 
and Health and National Center for Toxicological Research have developed risk 
assessment methods for mixtures, in the early 1980s (RAMAS, 2003). Since 
1996, U.S. EPA has been required by the Food Quality Protection Act, to include 
the evaluation of mixture risk assessment of chemicals (RAMAS, 2003; Rider et 
al., 2010). However, as discussed before, all regulatory threshold limits, such as 
tolerable daily intakes (TDI), are based only on individual chemical risk 
assessment. Furthermore, there is the question of whether it is safe to be 
exposed to chemicals in mixture at low levels; although Carpenter et al. (2002) 
pointed out that there might not necessarily be interactions among all chemicals 
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in a mixture. Those chemicals that share the same site of action could result in 
non-additive effects. Despite the importance of exposure to mixtures, until now, 
risk assessments have largely focused on single and multiple routes of exposure 
to individual chemicals (Sexton and Hattis, 2007).  
 
It is particularly important in the case of drinking water contamination to consider 
both mixture effects and multi-route exposure while establishing guideline values; 
however, this has not yet been done. The interactions could occur to different 
degrees according to the route of exposure. The present study focused on the 
use of in vivo data and PBPK models to evaluate the impact of multiple routes of 
exposure on the kinetics of a chemical mixture. For this purpose, VOCs 
representative of the substances found in large volume petroleum products (e.g., 
gasoline, kerosene, gas oil) that could potentially contaminate water supplies 
were selected (toluene, n-hexane, cyclohexane and isooctane). In general, 
petroleum products contain mostly carbons (84-87%) and hydrogens (11-14%), 
other elements being present in much lower proportions. Table 1 represents the 
major classes of chemicals present in petroleum hydrocarbon products (Hyne, 
2001). 
 
Table 1: Major classes of chemicals present in petroleum hydrocarbon products. 
 
Chemical class Weight (%) 
Paraffin (alkane) 30 
Naphthenes (cycloalkanes) 49 
Aromatic 15 
Asphaltic 6 
 
 
Substances chosen in this study belong to different families of hydrocarbons 
found in crude oil, as well as gasoline. For instance, while toluene represents the 
aromatic hydrocarbon family, n-hexane, cyclohexane and isooctane belong to 
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straight-chain paraffins, naphthenes and branched-chain paraffin, respectively 
(Chen et al., 1998). The following section presents a brief summary of the 
toxicokinetics and toxicity characteristics of these VOCs. 
 
1.2. Toxicokinetics and toxicity of toluene, n-hexane, cyclohexane and 
isooctane 
 
Table 2: Summary of key toxicokinetics and toxicity features of toluene, n-
hexane, cyclohexane and isooctane. 
 
  Toluene n-Hexane Cyclohexane Isooctane 
Principal 
absorption 
route 
Respiratory 
Oral 
Respiratory
 
Respiratory 
Oral 
Oral 
Metabolite  Hippuric 
Acid 
2,5-
hexanedione
Cyclohexanol 2,4,4-
trimethylpentanoate 
Site of 
metabolism 
Liver Liver Liver Liver 
Target Site CNS PNS CNS Kidney 
In male rat 
TLV®(ppm) 50 50 300 300 
 
TLV®: threshold limit value®; CNS: central nervous system; PNS: peripheral 
nervous system 
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1.2.1. Toluene (C6H5CH3) 
 
1.2.1.1. Toxicokinetics 
 
Toluene is a colorless liquid, volatile, miscible and almost insoluble in water (U.S. 
EPA, 2005). Its ability to prevent engine knocking and its high research octane 
number (RON=111) makes it a good fuel additive in order to achieve a better 
performance of the engine (Sarmaneav et al. 1980). 
 
The extent of absorption following oral dosing (provided through feeding tubes) of 
volunteers at a rate of 2 mg/min of toluene for a period of 3 hours was almost 
100% (Baelom et al., 1993). However, absorption rate has been reported lower 
for inhalation exposure. In fact, it has been shown that the retention is higher 
after a single lower dose exposure (83% - 189 mg/m3) compared to a single 
higher dose exposure (50% - 300 mg/m3) (Benoit et al., 1985; Carlsson et al., 
1982). In rats, researchers suggest that absorption of toluene happens, in 
average, faster after inhalation exposure (1-2 hours) than oral exposure (1.3- 6.3 
hours) (Gospe and Al-Bayati, 1994). Overall, absorption from the gastrointestinal 
route is as important as the respiratory system when exposure lasts for about an 
hour. On the other hand, during short exposures, 85-90% of toluene is absorbed 
via the respiratory tract (Faust, 1994). 
 
To find out the skin capacity to absorb toluene, volunteers were exposed to liquid 
toluene and toluene from aqueous solution (Dutkiewicz and Tyras, 1967). The 
authors showed that, for a mean concentration of 180-600 mg/l, the absorption 
rate of liquid toluene was 14-23 mg/cm2/h compared to 0.16-0.6 mg/cm2/h for the 
aqueous solution. They concluded that in both cases absorption rate increases 
with increases in toluene concentration. Although Gospe and Bayati (1994) 
mentioned that skin should be considered as an important exposure route, the 
U.S. EPA (1990) reported that skin absorption accounts for only 1% of the 
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inhalation route. Therefore, it was concluded that because of the strong volatile 
character of toluene, skin is not an important absorption route (U.S. EPA, 1990).  
Liver is the main organ of toluene metabolism (U.S. EPA, 1990). Toluene is 
metabolized by the family of cytochromes P450, principally by CYP2E1 and 
CYP2B1/B2 in liver, mostly into hippuric acid (HA) (Nakajima et al., 1991). It is 
eliminated principally through the urinary system (80%) as HA and as unchanged 
substance through exhalation (20%) (Nakajima et al.,1997). 
 
1.2.1.2. Toxicity  
 
In a two-year inhalation study, female and male F344/N rats were exposed to 
600 to 1200 ppm of toluene. No evidence of carcinogenic activity in either male 
or female was observed (NTP, 1990). The U.S. EPA and International Agency for 
Research on Cancer (IARC) have classified it, according to their ranking system, 
in group D and 3, respectively. The threshold limit value (TLV)® for toluene was 
established at 50 ppm.  
 
The most important effect of inhalation exposure to toluene is on the central 
nervous system and the brain in both humans and animals (Filley et al., 2004). 
Chronic exposure in workers at 30 to 150 ppm could result in hearing loss, color 
vision impairment and lower performance in neurobehavioral tests (ATSDR, 
2000). Furthermore, effects on the reproductive system and development in 
children whose mothers were exposed to high concentrations of toluene during 
pregnancy have been reported (Bowen et al., 2006). Other effects have been 
reported on the respiratory, cardiovascular, hematological, hepatic and renal 
systems (ATSDR, 2000). 
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1.2.2. n-Hexane (C6H14) 
 
 1.2.2.1. Toxicokinetics 
 
n-Hexane is highly volatile, colorless and slightly soluble in water. However, 
unlike toluene it is not an additive but a natural component of fuel (WHO, 1991). 
The respiratory tract is the main absorption route of n-hexane, but it can also be 
absorbed by the gastrointestinal tract and the skin (Bonnard et al., 2008). On the 
other hand, absorption of n-hexane via the skin is not significant (Stellman, 
1998). 
 
 n-Hexane is metabolized in the liver by CYP2B1 into 2,5-hexanedione (HD) 
(Fabioano et al., 2010). It is eliminated either by the respiratory or urinary system 
(U.S. EPA, 2005). Up to 10% of unchanged n-hexane is eliminated by exhalation 
with an estimated half-life of 100 minutes. However, it is mostly eliminated in 
urine as 2-hexanol (60-70%), a urinary metabolite with a half-life of about 12hrs 
(ATSDR, 1999). 
 
 1.2.2.2. Toxicity 
 
n-Hexane affects mostly the peripheral nervous system (Ali and Tardif, 1999).  
Based on their observation, workers who have been exposed for long periods of 
time complained about numbness in their arms and feet followed by paralysis. 
However, they recovered six months to one year after being removed from the 
contaminated environment. There is no evidence for human or animal 
carcinogenicity of n-hexane. It has not been classified as a carcinogen by U.S. 
EPA (group D). TLV® for n-hexane is 50 ppm.  
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1.2.3. 2,2,4-Trimethylpentane (Isooctane, C8H18)  
                                 
 1.2.3.1. Toxicokinetics 
 
Isooctane is a colorless liquid, insoluble in water and soluble in toluene and 
benzene. Its chemical conformation increases the capacity of fuel to burn and 
reduces the knocking problem of engines (U.S. EPA, 2006). Therefore, by 
definition isooctane is given the RON of 100. Conversely, with a RON of zero, 
heptane has the poorest fuel burning capacity, and comparison between these 
two substances determines the octane number of other hydrocarbons in fuel. 
 
Studies show a high rate of oral absorption (almost 95% of the oral dose) and a 
lower absorption rate after respiratory exposure (7-12% of the administrated 
dose) in rats (Kloss et al., 1986). Isooctane is metabolized by P450 mainly into 
pentanoic acids and 2,4,4-trimethy-2-penthanol (Olson et al., 1985; El-masri et 
al., 2009). The majority of metabolites are eliminated in urine (67% for males, 
50% for females). However, it has been reported that 90% of the absorbed dose 
after inhalation exposure is eliminated from the respiratory system after about 
70hr. It will be as much as 43% in males and 49% in females from exhalation 
(Kloss et al. 1986). 
 
 1.2.3.2. Toxicity 
 
Studies have shown that isooctane induces proximal tubular tumor in male rats 
(Swann et al., 1974). This happens after its metabolite, 2,4,4-trimethy-2-
penthanol, binds to α2u-globulin protein which results in a  complex that leads to 
the development of tumor in this part of kidney. The protein α2u-globulin is 
specific to male rats (Charbonneau et al. 1987; El-masri et al., 2009) and 
therefore isooctane nephrotoxicity/carcinogenicity is not considered to be 
relevant for humans by the U.S. EPA and other scientific/regulatory agencies. 
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1.2.4. Cyclohexane (C6H12) 
 
 1.2.4.1. Toxicokinetics 
 
Cyclohexane is a colorless liquid, slightly soluble in water. It is part of natural 
chemical substances found in crude oils and also a part of gasoline (U.S. EPA, 
2003).  
 
Espinosa-Aguirre et al., (1997) reported that cyclohexane is metabolized into 
cyclohexanol and to a lesser extent into cyclohexanone by CYP2B4 in the liver. 
They observed that cyclohexanol induces CYP2E1 and CYP2B1/B2 isozymes 
that are involved in the metabolism of toluene and n-hexane. Therefore, it is 
possible to speculate that the effects resulting from exposure to toluene and n-
hexane separately can be different if exposure is to a mixture of cyclohexane, 
toluene, and n-hexane. Elimination of cyclohexane and its metabolites happens 
primarily via exhalation. Only 20% of elimination occurs via the urinary system 
(U.S. EPA, 2003).  
 
 1.2.4.2. Toxicity 
 
No adequate human epidemiological studies are available on cyclohexane. Most 
animal studies suggest effects on the central nervous system. However, liver 
hypertrophy and differentiation in liver enzyme profile have also been mentioned 
(U.S. EPA, 2003).  
 
1.3. Previous studies on multi-route exposures and interactions among 
toluene, n-hexane, cyclohexane and isooctane 
 
Until now, there has been no study on interactions between these four chosen 
chemicals. There have been, however, two studies on binary exposure to toluene 
and n-hexane. The first study showed that exposure to the mixture of 1000 ppm 
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toluene and 1000 ppm n-hexane via the respiratory system, resulted in a 
reduction of the neurotoxic effects of n-hexane, compared to exposure to n-
hexane alone (Takeuchi et al., 1981). The authors suggested that toluene 
reduces the oxidation rate of n-hexane to 2,5-hexanedione (HD). In the second 
study, Ali and Tardif (1999) also found a significant reduction of urinary HD (75%) 
after respiratory exposure to the mixture of 300 ppm toluene and 100 ppm 
hexane. However, these authors reported that amounts of hippuric acid (HA) (ie., 
toluene metabolite) did not decrease significantly (only by up to 25%).  
 
There is no research about mixture exposure including cyclohexane or isooctane. 
However, one study reported that cyclohexanol (i.e., metabolite product of 
cyclohexane) induces CYP2E1 and CYP2B1/B2, indicating a potential for 
interaction with other chemicals (Espinosa-Aguirre et al., 1997). As these 
cytochromes are involved in the metabolism of toluene and n-hexane, 
hypothetically, simultaneous exposure to toluene, n-hexane and cyclohexane, 
can lead to metabolic interactions between them. However, neither experimental 
data nor predictive PBPK models are available to evaluate the relevance of 
occurrence of interactions among these substances for risk assessment 
considerations.  
 
1.4. Objective and originality of this study 
 
The general objective of this project is to evaluate the importance of both mixture 
and multi-route exposures in perspective of establishing better guidelines for 
chemicals in drinking water.  
 
First, this study focused on developing PBPK models and comparing them to 
experimental data to determine the kinetics of individual chemicals by a single 
route (i.e., inhalation and ingestion) and multiple routes of exposure (Article 1). 
Then, the PBPK models were applied to simulate the kinetics of hydrocarbons 
(toluene, n-hexane, cyclohexane and isooctane) following mixed exposure via 
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multiple routes, in an effort to compare the outcome with those of individual 
chemical exposures via single or multiple routes (Article 2). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Article 1 
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Short abstract 
 
Physiologically based pharmacokinetic (PBPK) models, as well as in vivo 
experiments were used in order to characterize the impact of simultaneous 
exposure by inhalation and oral gavage (aggregate exposure) on the total 
internal dose of n-hexane or isooctane in rats. The PBPK models developed in 
this study are useful tools for simulating kinetics of hydrocarbons, by accounting 
not only for the saturable metabolism but also the possible kinetic behavior 
during aggregate exposures. 
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Abstract 
 
The objective of this study was to compare the results of the aggregate exposure 
(inhalation and gavage) to n-hexane or isooctane to the simple exposure 
(inhalation) on the total internal dose of the substances. Physiologically based 
pharmacokinetic (PBPK) models, as well as in vivo experiments were used in 
order to simulate the kinetics of each chemical for simple and aggregate 
exposure. First, experimental data were collected from simple exposure of male 
Sprague-Dawley rats (n=5) exposed to n-hexane or isooctane (2,2,4-
Trimethylpentane; TMP) by inhalation (50 ppm or 200 ppm n-hexane, 300 or 
1200 ppm isooctane) or oral gavage (5.5 or 22.3 mg/kg n-hexane, 40 or 162 
mg/kg isooctane). Next, other groups of rats were exposed to each substance 
simultaneously by inhalation and oral gavage. Blood concentration was 
measured between 2-6 hours after inhalation and aggregate exposure, and 0.5-3 
hours after oral gavage. The PBPK model could fit the experimental data of 
different exposure scenarios and also was validated by the data-derived area 
under the blood concentration vs time curve mg/l. min. PBPK models as well as 
experimental data suggest that the internal dose resulting from aggregate 
exposure to n-hexane is not additive of the sum of the internal doses resulting 
from individual exposure routes. However, results from multi-route exposure to 
isooctane show that it is additive of the sum of the results from simple exposure 
routes. The PBPK models developed in this study are useful tool for simulating 
the kinetics of hydrocarbons, by accounting not only for the saturable metabolism 
but also for the possible kinetic behavior during aggregate exposures. 
 
Keywords: PBPK, multi-route exposure, VOC, n-hexane, isooctane 
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Introduction 
 
Contamination of ground water with petroleum products (i.e., gasoline) has 
widely preoccupied the regulatory agencies such as the U.S. EPA (Andelman, 
1985). The main reason for this attention is the extended use of petroleum 
products and therefore the greater possibility of underground water 
contamination due to the leakage of fuel from containers of gas stations (U.S. 
EPA, 1990). In this study, n-hexane and isooctane (2, 2, 4-Trimethylpentane; 
TMP) are chosen to represent two different chemical classes in petroleum 
products (i.e., gasoline). n-Hexane and isooctane exemplify classes of alkanes 
and branched chain paraffins, respectively (Chen et al., 1998). n-Hexane is 
present in as much as 11% of crude gasoline (U.S. EPA, 2005). The neurotoxic 
effects of n-hexane have been reported in both animals and humans (Takeuchi 
et al., 1981; Filser et al., 1987; Hamelin et al., 2005). Isooctane is an additive to 
unleaded gasoline and is used to increase the octane number of fuel and the 
performance of the engine (Lock et al., 1993, El-Masri et al., 2009).  The 
neurotoxic effects of isooctane have been reported in experimental animals 
(Swann et al., 1974; El-Masri et al., 2009). However, it is mostly known for its 
nephrotoxicity in male rats, which is not relevant to humans (Fowlie et al., 1987; 
Lock et al., 1993). Liver damage due to exposure to isooctane in rats has also 
been reported (Fowlie et al., 1987). 
 
Both n-hexane and isooctane are volatile organic compounds (VOCs). VOCs 
possess low water solubility, high vapor pressure and low molecular weight (Liu 
and Zhou, 2011). These characteristics give them the capacity and mobility to 
contaminate different layers of soil and therefore underground water (U.S. EPA, 
1990). As a result, consumers at home can be exposed to these chemicals from 
drinking water during bathing and showering or simply by inhaling the indoor air 
(Mckone, 1999). For years, regulatory agencies had considered the oral route to 
be the main exposure route to contaminated drinking water (McKone, 1999; 
reviewed in Krishnan and Carrier, 2008). Later, studies were able to show that 
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because of the efficient transfer from water to air, the inhalation route is an 
important exposure route for VOCs (Andelman, 1985; McKone, 1987, 1999).  
Several studies have shown that dermal exposure also contributes to the total 
absorbed dose depending upon the dose and physiochemical characteristic of 
the substance and duration of skin contact (Brown et al., 1984; McKone, 1999; 
Xu et al., 2002; Krishnan and Carrier, 2008).  
 
Today, the significance of multiple routes of exposure (inhalation, gastrointestinal 
and dermal) to VOCs is widely recognized. However, conducting experimental 
studies with multiple chemicals for different scenarios of exposure, doses, and 
routes seems practically impossible (Haddad et al., 2001). PBPK modeling is a 
proven tool that makes it possible to evaluate the different pharmacokinetic 
phases such as absorption, distribution, metabolism and excretion in animals as 
well as humans regardless of the exposure scenario (Haddad et al., 2001; 
Dennison et al., 2004).  
 
The objective of this study was to develop PBPK models to simulate the 
pharmacokinetics of n-hexane and isooctane after multi-route exposures. This 
approach would help better understand the effects of aggregate exposure on the 
internal dose of these chemicals in rats and the capacity of PBPK models to 
simulate multi-route exposure scenarios. 
 
Materials and Methods 
 
1) In vivo study 
 
Chemical 
 
n-Hexane (99%) and isooctane (anhydrous 99.8%) were obtained from Aldrich 
chemicals (Milwaukee, WI). 
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Animals 
 
Adult male Sprague-Dawley rats (240-260 g) were obtained from Charles-River 
Canada (St-Constant, Québec). They were housed in temperature-controlled 
cages in groups of two or three per cage with a 12-h light–dark cycle. A minimum 
one week acclimatization period was provided. They were given food and water 
ad libitum until the day of experiment. On the day of experiment they were placed 
in individual cages and fasted during the experiment. 
 
Exposure scheme 
 
Inhalation exposure 
 
Groups of male Sprague-Dawley rats (n=5) were separately exposed to low and 
high concentrations of each substance by inhalation (50 ppm and 200 ppm of n-
hexane; 300 ppm and 1200 ppm of isooctane; 2-hr) in a closed-atmosphere 
exposure system (Haddad et al., 2000). The concentrations were monitored 
using automatic injection of 0.25 ml air samples into a gas chromatograph (HP 
5890) equipped with a flame ionization detector (FID). Helium was used as a 
carrier gas, at the rate of 5.4 ml/min.  
 
Oral exposure 
 
Groups of rats (n=5) were given a single low dose or high dose of the 
substances. Accordingly, 5.5 mg/kg or 22.3 mg/kg of n-hexane, and 40 mg/kg 
and 162 mg/kg of isooctane were diluted in Alkamuls® (10%). Ten ml of solution 
was administered per kg body weight. 
 
 
 
 
  
24
Dermal route 
 
In this study, the dermal exposure was omitted as a relevant absorption route 
because at the exposure levels chosen on the basis of the threshold limit values 
of n-hexane (50 ppm) and isooctane (300 ppm), the dermal route did not appear 
to contribute significantly to the systemic dose (Bonnard et al., 2008; U.S. EPA 
2007; Faust, 1994). Moreover, the preliminary experiments in rats determined 
that neither n-hexane (1.39 mg/ml) nor isooctane (10.18 mg/ml) is absorbed 
significantly by the dermal route (results not shown). 
 
Multi-route exposure 
 
A group of rats (n=5) was given a single oral dose of 22.33 mg/kg of n-hexane 
and then placed within a closed-chamber system for inhalation exposure to 200 
ppm during 2 hr. In the case of isooctane, two groups of rats (n=5) were orally 
administered with either 40 mg/kg or 162 mg/kg and then exposed to an 
atmosphere of 300 ppm or 1200 ppm for 2 hr.  
 
Analysis of the blood concentration 
 
Blood samples (25-200 µl) were collected by performing a small incision on the 
tail veins of rats. The concentration of unchanged substances in blood was 
quantified using a head-space gas chromatography method (Tardif et al., 1993). 
After single oral exposure, blood samples were taken from animals 0.5, 1, 1.5, 2, 
2.5 and 3 hr post-exposure. For the inhalation and multi-route exposure, 
however, blood samples were taken 2, 2.5, 3, 3.5, 4 and 5 hr post- exposure. 
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2) PBPK Modeling 
 
Model representation 
 
The four-compartmental PBPK models were developed similar to Haddad et al. 
(2000) separately for n-hexane and isooctane. The compartments of the PBPK 
model were: liver (as the metabolizing tissue), fat, richly-perfused tissues and 
slowly-perfused tissues, all connected by systemic blood circulation and gas 
exchange in the lung (Figure 1). In order to simulate oral and multi-route 
exposures, the gastrointestinal tract was included (Haddad et al., 2000). 
Accordingly, the stomach was described as additional portal of entry. The 
absorption rate from the stomach and constituted the systemic input of the orally-
administered chemicals investigated in this study. The transfer of unabsorbed 
chemical from the stomach to the intestine has also included, and it was found to 
be essential to obtain reasonable model fit experimental data on oral kinetics. 
 
Model parameterization 
 
The physiological parameters of the rat as well as physiochemical parameters 
(i.e., partition coefficients and metabolic constants) for n-hexane were taken from 
Ali and Tardif (1999) whereas that of isooctane was obtained from El-Masri et al. 
(2009) (Table 1-2). The rate of metabolism (Amet/dt) in this model was described 
as a saturable process using Vmax (maximal velocity) of 1.35 mg/kg/h and Km 
(Michaelis-Menten affinity constant) of 0.4 mg/l for n-hexane as obtained from Ali 
and Tardif (1999). The values of Kx (absorption rate constant for stomach) and 
Ko (stomach to intestine transfer constant) were obtained by fitting the PBPK 
model simulations to kinetic data for the oral route, and this yielded estimates of 
0.2 min-1 and 0.007 min-1, respectively. 
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For isooctane, the Vmax of 0.3 mg/h and Km: 1 mg/l were fitted to the inhalation 
PBPK model. Kx: 0.001 min¯¹ and Ko: 0.003 min¯¹ were obtained by fitting PBPK 
model simulation to the oral gavage data.  
 
The metabolism was considered to take place exclusively in the liver. The rate of 
the change in the amount of chemical (dAt/dt) for this compartment accounted for 
the metabolism rate as follow (Haddad et al., 2000): 
 
  max  ( - )
 
-dAt Cvl x VQl Ca Cvl
dt Cvl Km
=
+
                                                                      [1] 
 
where:   
Ql: rate of blood flow through the liver 
Ca: concentration of solvent in the arterial blood, and 
Cvl: concentration of solvent in the blood leaving the liver 
And for oral and multiple exposure routes (Haddad et al., 2000) 
 
  max  ( - ) ( )
 
- abdAt Cvl x VQl Ca Cvl A
dt Cvl Km
= +
+
                                                            [2] 
 
where: 
Aab: rate of chemical being absorbed during the oral exposure (mg/h). It was 
calculated as:   
 
Aab= Kx × Qt                                                                                                           [3] 
 
where: 
Kx: absorption rate constant of a chemical by the stomach (min-1) 
Qt: remaining quantity of chemical in the stomach (mg) 
Transfer of the remaining chemical from stomach to intestine was included as: 
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Qt = Q – (Aab × ta) – (Ko × ta × Aab)                                                             [4] 
 
 where  
Ko: stomach to intestine transfer constant (min¯¹) 
ta: interval of time (min) 
 
Statistical analysis and model evaluation 
The statistical analyses were conducted using SPSS for Windows (v15.0.0, 
Chicago, IL, USA). In order to validate the model, data-derived area under the 
blood concentration vs. time curves (AUC; mg/L x min) were obtained for every 
exposure scenario (inhalation, gavage and multi-route) and dose (low and high 
doses), and compared with those obtained using the PBPK model. The results 
were used to determine the degree of discrepancy between PBPK modeling and 
experimental data. 
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Results 
 
Single route exposure: inhalation or oral gavage  
 
n-Hexane 
 
The experimental data and PBPK model simulations after 2-hr inhalation 
exposure of rats to 50 ppm and 200 ppm n-hexane are presented in Figure 2A. 
Blood elimination rate (Kel) and half-life of n-hexane based on the experimental 
data (2-6 hr) were estimated as 1.22 hr-1 and 0.56 hr for the low dose and 0.84 
hr-1 and 0.82 hr for the high dose, respectively. After 2-hr exposure to 50 ppm, 
maximum blood concentration of unchanged n-hexane (Cmax) was 0.09 ± 0.01 
mg/l vs. 0.13 mg/l, respectively, as indicated by the experimental data and the 
PBPK model. In contrast, Cmax after exposure to 200 ppm were 0.45 ± 0.02 mg/l 
according to experimental data vs. 0.66 mg/l for PBPK model. The data-derived 
area under the blood concentration (AUC) after exposure to 50 ppm n-hexane by 
inhalation was 3.29 mg/l.min vs. 4.5 mg/l.min as simulated by the PBPK model 
(2- 4 hr). The AUCs of high dose exposure as obtained from experimental data 
and PBPK model were 20.75 mg/l.min vs. 20.25 mg/l.min, respectively. 
Figure 2B compares the experimental data with PBPK model simulations after a 
single oral dose exposure to n-hexane. The experimental data from single oral 
exposure to high dose n-hexane could well fit our PBPK model (Figure 2B). The 
values of Kx (absorption rate constant for stomach) and Ko (stomach to intestine 
transfer constant) obtained by fitting were 0.2 min-1 and 0.007 min-1, respectively. 
The only measurable concentration after exposure to 5.53 mg/kg dose of n-
hexane occurred at 0.5 hr post-exposure (0.016± 0.006 mg/l). After that, n-
hexane was not detectable in blood. Following the administration of 22.33 mg/kg, 
the Cmax observed 10 minutes post-dosing was 0.3 mg/l whereas the AUC 
based on experimental data was 21.06 mg/l.min The PBPK model-simulated 
Cmax and AUC for high dose exposure were 0.26 mg/l and 13.01 mg/l.min, 
respectively.  
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Isooctane 
 
The PBPK model adapted for isooctane has been compared to the experimental 
data after 2-hr inhalation exposure to low (300 ppm) and high (1200 ppm) 
concentrations in Figure 3A. Figure 3B shows a significant correlation between 
the experimental data and the PBPK model from both low dose (40 mg/kg) and 
high dose (162 mg/kg) gavage exposure. Kx and Ko were fitted at 0.001 min-1 
and 0.003 min-1, respectively. 
Based on results from experimental data (2-6 hr), the Kel and half-life of 
isooctane were 0.39 hr-1 and 1.76 hr after exposure to 300 ppm, and 0.30 hr -1 
and 1.15 hr after exposure to 1200 ppm of isooctane, respectively. The Cmax 
from experimental data was 1.25 ± 0.04 mg/l compared to 2.68 mg/l from the 
PBPK model after 2-hr exposure to 300 ppm. After exposure to 1200 ppm, Cmax 
from experimental data was 5.06 ± 0.35 mg/l vs. 11.07 mg/l from the PBPK 
model. The AUC after 2-hr exposure to 300 ppm (2-6 hr) from experimental data 
vs PBPK model were 73.36 mg/l.min and 68.48mg/l.min. At 1200 ppm it was 
295.58 mg/l.min vs. 287.72 mg/l.min, respectively. 
The PBPK model could adequately simulate the kinetics of isooctane after 2 hr 
exposure of rats to low and high concentrations by inhalation route (Figure 3A).  
The ability of PBPK model to evaluate a single oral gavage exposure at low (40 
mg/kg) and high (162 mg/kg) concentrations is shown in Figure 3B. Kel and half-
life were 0.66 hr-1 and 1.04 hr after exposure to low dose, and 0.31 hr-1 and 2.2 
hr after exposure to high dose, respectively.  Cmax of low dose exposure based 
on the experimental data was 1.26 mg/l vs 1.13 mg/l from the PBPK model. After 
exposure to high dose, this amount increased to 1.8 mg/l and 3.6 mg/l for 
experimental data and PBPK model, respectively. The AUCs of PBPK model and 
experimental data (0.5-6 hr) were at low dose 148.61 mg/l.min and 135.51 
mg/l.min, and at high dose 663.66 mg/l.min and 477.47 mg/l.min, respectively.  
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Multiple routes of exposure by inhalation and oral gavage 
 
n-Hexane 
 
Figure 2C compares PBPK model simulations with experimental data after 
simultaneous exposure of rats to n-hexane by inhalation and oral gavage. The 
values of Kx and Ko used in PBPK model of multi-route were the same as those 
used for simulating single route (oral) exposures (0.007 min-1 and 0.2 min-1). 
Figure 2C also compares results from multi-route exposure to the sum of data 
obtained for the two single routes (inhalation and oral gavage) in the initial 
experiments. 
Following multi-route exposures to 22.33 mg/kg (oral gavage) and 200 ppm 
(inhalation), Kel and half-life based on experimental data were 1.025 hr-1 and 
0.67 hr, respectively. Cmax of n-hexane after multi-route exposures compared to 
the sum of the two single routes were 0.5 mg/l vs. 0.68 mg/l. The AUC from 
experimental data and PBPK model were 37.59 mg/l.min vs 27.25 mg/l.min. The 
ratio of AUC between multi-route exposure and the sum of single route exposure 
was 0.64.  
 
Isooctane 
 
Figure 3C depicts the PBPK model simulations of the blood concentration vs. 
time course after multi-route exposure to isooctane in rats at low dose (40 mg/kg 
+ 300 ppm) and at high dose (162 mg/kg + 1200 ppm). The same values of Kx 
and Ko (0.001 min-1 and 0.003 min-1) used for oral exposure of the PBPK model, 
were used in the PBPK model of multi-route exposure. 
The Kel and half-life of isooctane after multi-route exposure were 0.36 hr-1 and 
0.67 hr after low dose vs 0.35 hr-1 and 1.97 hr after high dose exposure. The 
Cmax of unchanged isooctane in the blood stream were 1.7 mg/l and 7.3 mg/l, 
respectively after low and high concentrations, after multi-route exposures. The 
AUCs calculated from PBPK model and experimental data were respectively 
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184.07 mg/l.min vs 148.56 mg/l.min after low dose, and 798.26 mg/l.min vs. 
688.07 mg/l.min after high dose exposure. The ratios of the AUC between 
experimental data from multi-route and the sum of the single exposure (low and 
high dose) routes were 1.1 and 0.91, respectively. 
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Discussion 
 
The PBPK model developed in this study was able to predict the kinetics of n-
hexane and isooctane in rats following inhalation exposure and oral gavage. The 
systemic concentration of each chemical as a function of time after inhalation 
exposure, oral gavage or multiroute exposures was obtained using PBPK models 
and compared with experimental data. Previous experimental studies on the 
kinetics of n-hexane have primarily focused on the inhalation exposure in 
humans or rats (Bus et al., 1979; Veulemans et al., 1982; Perbellini et al., 1985; 
Gargas et al., 1989; U.S. EPA 2005). Interestingly, the tissue:air partition 
coefficients reflecting the volume of distribution in humans, were found to be 
comparable to that of F344 rats (example: 5.0, 5.2 and 104 for human muscle, 
liver and fat (Perbellini et al., 1985) vs. 2.9, 5.2 and 159 for rat muscle, liver and 
fat (Gargas et al., 1989)). No study on the kinetics of uptake and distribution of n-
hexane after oral administration is yet available (U.S. EPA 2005).  
 
In contrast, the pharmacokinetics of isooctane has been investigated by the oral 
route. Reviewed in U.S. EPA (2005), the study of Kloss et al. (1986) on the 
distribution of isooctane in F344 rats after single oral administration 
demonstrated sex-specific differences in the radioactivity in different organs (i.e., 
liver, heart, testis, kidney and spleen) 72 hrs after single oral administration of 
500 mg/kg of this substance. The majority of isooctane was found in the kidney 
and its accumulation was 8 to 10-fold greater in male rat kidney than female 
(1225 nmol equivalent [eq]/g of wet tissue compared to 157 nmol-eq/g wet 
tissue). Following this study, Charbonneau et al. (1987) demonstrated that in the 
female rat, the concentration of 14C labeled isooctane in kidney, plasma and liver 
decreased significantly at 8 hrs after oral administration, whereas it remained 
fairly constant even after 12 to 24 hrs post-exposure in male rats (U.S. EPA 
2005).  
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There are limited efforts on the development of PBPK models for isooctane (El-
Masri et al., 2009) and n-hexane (Ali and Tardif, 1999; Yu et al., 1998; Dennison 
et al., 2004; Hamelin et al., 2005). All these modeling studies have focused only 
on inhalation exposure. In the present study, for the first time, not only the PBPK 
model was used to simulate inhalation and oral exposures separately but also 
the model was applied to simulate combined exposure via inhalation and oral 
routes.  
 
n-Hexane 
 
After 2-hr exposure to a lower concentration of 50 ppm or 0.18 mg/l of n-hexane 
in the rat, the maximum blood concentration decreased by 50% to 0.09 ± 0.01 
mg/l in blood vs. 0.13 mg/l simulated by the PBPK model. However, at the high 
concentration of 200 ppm or 0.72 mg/l, it decreased by about 40% in 2 hrs and 
the resulting blood concentration was 0.45 ± 0.02 mg/l vs. 0.66 mg/l as simulated 
by the PBPK model. Comparable blood concentration (0.45 ± 0.1 mg/l) has been 
reported by Bus et al. (1979) after 6-hr exposure to 1000 ppm (3.5 mg/l) n-
hexane in pregnant rats. Furthermore, Filser et al. (1987) with mathematical 
analyses showed that, for inhaled concentrations below 300 ppm, the 
metabolism of n-hexane is directly proportional to its atmospheric concentration, 
whereas at higher concentrations (i.e., >300 ppm), metabolism is non-linear and 
saturated.  
 
No previous experimental study or PBPK modeling has focused on the oral 
absorption kinetics of n-hexane. However, neurotoxic effects of n-hexane 
following oral dosing of rats have been reported (U.S. EPA, 2005). In the study of 
Ono et al. (1981), n-hexane was not detectable after a single oral dose (5.53 
mg/kg). Bonnard et al. (2008) corroborated these findings on the basis of the 
marked pulmonary clearance of n-hexane. Similarly, in the present study, no data 
could be obtained from oral exposure at lower concentration (5.53 mg/kg), 
because the concentrations were below the limit of quantification. Therefore 
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multi-route exposure to n-hexane was only performed at higher dose (200 ppm + 
22.33 mg/kg) by inhalation and oral routes. The dermal route was ignored in 
these experiments after the preliminary experiments showed that at the doses 
used in this study, the dermal route did not significantly contribute to the total 
internal dose (Gagné, 2008). The PBPK model of multi-route exposures used in 
this study could fit the results from in vivo experiments (Figure 2C). Same values 
of Ko: 0.003 and Kx: 0.007 from oral exposure study, were used for simulating 
multi-route exposures. Results from both single and multi-route exposures were 
used to determine if simultaneous exposure to n-hexane by inhalation and oral 
gavage could have an additive effect. A perfect additive effect between single 
and multi-route exposures was not observed, except during the first 30 min of 
post-exposure (Figure 2C). 
 
Isooctane  
 
This is the first study of PBPK modeling of isooctane following oral dosing and 
multi-route exposure. Previous experimental studies in rat reported neurotoxicity 
following inhalation exposure (Swann et al., 1974; U.S. EPA 2006), or 
development of a PBPK model of inhalation exposure to isooctane (El-Masri et 
al., 2009). El-Masri et al. (2009) reported biphasic diminution of isooctane with 
the rapid phase indicative of absorption, distribution and metabolism of the 
substance, and the slower phase corresponding to the elimination part. The 
pharmacokinetic data collected and modeled in the present study reflect the 
same pattern. Right after 2-hr exposure to 300 ppm (1.42 mg/l), the blood 
concentration of isooctane was 1.25 mg/l. However, 30 minutes later, it dropped 
by almost 64% to 0.45 mg/l. The blood concentration at 180, 210, 270 and 360 
minutes dropped at a much lower rate in rats, post-exposure, in both the low and 
high dose groups. Overall, the PBPK model used in this study could simulate well 
the inhalation kinetics of isooctane in rats (Figure 3A). 
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Based on the experimental data for inhalation routes, the derived Kel values are 
comparable for both exposure concentrations (i.e., 0.36 vs. 0.35 hr-1 for 300 ppm 
or 1200 ppm), indicating that there is no metabolic saturation. Similarly, the Kel 
associated with the high oral dose (162 mg/kg) was 0.31 hr-1, which is quite 
comparable. However, the Kel derived from the kinetic data for low oral dose (40 
mg/kg) was indicative of faster elimination. Figure 3C shows additive effect 
between single and multi-exposures routes at high dose. At lower dose, the 
perfect additive effect starts about 100 mins post-exposure. Overall, there are 
good correlations between the PBPK models and the experimental data.  
 
This study as well as that of others (Liao et al., 2007; Gagné, 2008) show that, 
internal dose of a substance after multiple routes of exposure is not always equal 
to the sum of the individual routes, although in the case of isooctane a good 
concordance was obtained. The PBPK model can be used as a reliable tool to 
simulate the effect of the single and multi-route on the internal doses.  
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Conclusion 
 
Overall, the PBPK model could demonstrate the effect of the multi-route 
exposures on the internal doses in the case of two VOCs (n-hexane and 
isooctane).  Investigations of the kinetic behavior of contaminants such as VOCs 
are important because of their volatile and lipophilic effect. VOCs can easily and 
abundantly contaminate underground water which will end up in drinking water 
and therefore human exposure to these chemicals. Having said that, humans are 
exposed not to a single chemical but to mixtures of chemicals every day 
(Konemann and Pieters, 1996). Hence, looking at the exposures as a mixture 
and not as a single chemical seems essential. Previous studies have shown the 
capacity of the PBPK model to simulate exposure to mixtures (Haddad et al., 
2001, 2010). However, there is no study on the capacity of PBPK models to 
represent an exposure to a mixture by multiple routes. Future research should 
therefore focus to develop a PBPK model that can simulate both multi-route and 
multi-chemical exposures.  
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Table 1: Physiological parameters in rats used in PBPK models for n-hexane and 
isooctane. 
 
Parameters                                                 Values¹         
Alveolar ventilation rate (L/h/kg)                 15          
Cardiac output (L/h/kg)                               15         
Blood flow rate (fraction of cardiac output)           
Liver                                                          0.25 
Fat                                                            0.09                           
Richly-perfused tissues                             0.51                         
Slowly-perfused tissues                            0.15          
Volume (fraction of body weight)          
Liver                                                         0.049    
Fat                                                            0.075                         
Richly-perfused tissues                            0.05          
Slowly-perfused tissues                           0.72              
 
¹ Ali and Tardif (1999) 
 
 
 
 
 
 
 
 
 
 
 
 
  
42
Table 2: Partition coefficients and metabolic constants of n-hexane and isooctane 
in rats 
 
Partition Coefficients 
 
n-Hexane1 
 
Isooctane2 
Blood:air 2.29 2.7 
Liver:air 5.2 10.7 
Fat:air 159 320 
Richly-perfused tissues:air 5.2 11.14 
Slowly-perfused tissues:air 2.9 4.3 
Metabolic Constants  
 
 
 
Vmax (mg/h/kg) 1.35 0.013 
Km (mg/L)   0.553 13 
        
        1 Ali and Tardif (1999) 
        2 El-Masri et al (2008) 
        3 Fitted values 
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List of Figures  
 
Figure 1: PBPK model of an aggregate exposure to a single chemical. 
[adipose tissue; FAT; richly-perfused tissues; RPT, poorly-perfused tissues; PPT; 
arterial blood (ART); venous blood (VEN)]. 
 
Figure 2A: Inhalation exposure: comparison of experimental data (symbols) and 
PBPK model simulation (black lines) of venous blood concentration (mg/l) versus 
time (min) following 2-hr exposure to n-hexane (50 ppm and 200 ppm) in rats.  
 
Figure 2B: Oral gavage exposure: comparison of experimental data (symbols) 
and PBPK model simulations (black lines) of venous blood concentration (mg/l) 
versus time (min) following single oral gavage exposure to n-hexane (22.33 
mg/kg) in rats. Groups 1 and 2 differ in the blood sampling times. The blood 
samples of group one were taken at 0.5, 1.0, 1.5, 2.0, 2.5, 3.5 hrs and group 2 
were obtained at 0.08, 0.17, 0.25, 0.5 and 1 hr post exposure. 
 
Figure 2C: Multiple routes of exposure: comparison of experimental data (filed 
squares) and PBPK model simulations (black lines) of venous blood 
concentration (mg/l) versus time (min) of single exposure by oral gavage (22.33 
mg/kg) followed by 2-hr inhalation exposure (200 ppm) to n-hexane. The ‘x’ 
symbol indicates the sum of the simple inhalation and oral gavage.  
 
Figure 3A: Inhalation exposure: comparison of experimental data (symbols) and 
PBPK model simulations (black lines) of venous blood concentration (mg/l) 
versus time (min) following 2-hr exposure to isooctane (300 ppm, 1200 ppm) in 
rats.  
 
Figure 3B: Oral gavage exposure: comparison of experimental data (symbols) 
and PBPK model simulations (black lines) of venous blood concentration (mg/l) 
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versus time (min) following single oral gavage exposure to isooctane (40 mg/kg, 
162 mg/kg) in rats.  
 
Figure 3C: Multiple routes of exposure: comparison of experimental data 
(symbols) and PBPK model simulations (black lines) of venous blood 
concentration (mg/l) versus time (min) of single exposure by oral gavage (40 
mg/kg, 162 mg/kg) followed by 2-hr inhalation exposure (300 ppm, 1200 ppm) to 
isooctane. The ‘x’ and ‘+’ symbols indicate the sum of the simple inhalation and 
oral gavage for the low dose and high dose, respectively.  
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Abstract: 
Mixture risk assessments focusing on both aggregate and cumulative exposures 
can be improved with an understanding of the change in internal dose. The 
modeling of the internal dose and pharmacokinetics of hydrocarbons following 
cumulative and aggregate exposures has not yet been undertaken. The objective 
of this study was to develop a PBPK model to simulate the mixed exposure to 
toluene, n-hexane, cyclohexane and isooctane (chosen to represent chemical 
classes in large volume petroleum products) by inhalation and oral routes in rats. 
PBPK models of individual chemicals were first developed, and were then 
interconnected using the metabolic interaction terms. The capacity of the PBPK 
model was evaluated by comparing it with experimental data. These data were 
collected in groups of male Sprague-Dawley rats (n=5) exposed to each 
substance by inhalation (50 ppm of toluene and n-hexane; 300 ppm of 
cyclohexane and isooctane) or oral gavage (8.3, 5.5, 27.9, and 41.27 mg/kg, 
respectively, for toluene, n-hexane, cyclohexane and isooctane) or to multi-
products given by both routes together at similar concentrations. The AUCs of 
experimental data were 157.25, 18.77, 117.57 and 176.54 mg/L.min whereas the 
AUC values derived from the mixture and multi-route PBPK model were: 121.73, 
21.91, 19.65 and 170.54 mg/L.min respectively, for toluene, n-hexane, 
cyclohexane and isooctane. Overall, the PBPK model developed in this study is a 
useful tool for simulating kinetics of hydrocarbon mixture, by accounting for the 
saturable metabolism and the interactive effects during aggregate and 
cumulative exposures. 
Keywords: Mixtures, PBPK modeling, hydrocarbons 
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Introduction 
 
Risk assessment methods for chemical mixtures in contaminated water continue 
to evolve (U.S. EPA, 2005; Simmons, 1995; Teuschler and Hertzberg, 1995; 
Yang et al., 1995). Underground water is the source of drinking water for more 
than 75% of cities in the United States (U.S. EPA, 1991). The release of 
petroleum products from damaged underground gas station containers is an 
important cause of underground water contamination (U.S. EPA, 1990; El-Kholy 
et al., 2009). The severity of the problem depends, first, upon the frequency and 
quantity of petroleum products released from these sources. In fact, it has been 
estimated that about 25% of five to six million storage tanks in the United States 
that contain fuel oil or gasoline are leaking (Shehata, 1985; U.S. EPA, 1990; 
Harris et al., 2008). Thus, the leakage as little as one drop of fuel per second 
could result in a total of 400 gallons of fuel released per year potentially 
contaminating underground water (Harris et al., 2008). Furthermore, the nature 
and the severity of the health consequences depend upon the hazardous nature 
of these petroleum products. 
 
Petroleum products contain large amounts of volatile organic compounds (VOC) 
(Labranche and Collins, 1996), some of which are added to gasoline in order to 
increase the burning efficiency of automobile engines (Pérez-Pavón et al., 2007). 
VOCs have low water solubility and high vapor pressure (Liu and Zhou, 2011) 
and therefore possess a marked capacity to be released from water to air 
(McKone, 1999). As a result, human exposure to these chemicals occurs via 
inhalation during and after bathing and showering simply by inhaling the indoor 
air (Mckone, 1999).  
 
For many years, the oral route of exposure to contaminated drinking water was 
considered alone in the risk assessment process (McKone, 1999; reviewed in 
Krishnan and Carrier, 2008). Additional studies demonstrated the importance of 
the inhalation route to the total exposure of VOCs during household use of 
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drinking water (Andelman, 1985; McKone, 1987; Weisel and Jo, 1996). The 
importance of the skin as an additional exposure route in the case of water 
contamination with VOCs has also been documented (Brown et al., 1984; 
McKone, 1999; Xu et al., 2002; Krishnan and Carrier, 2008). Therefore, there is 
an increasing focus on the consideration for aggregate or multiple exposures to 
these contaminants in the environment (Newill, 1989; FSA, 2002; Rider et al., 
2010).  
 
The presence of a great variety of components and different blends of them, and 
the numerous different possible interactions between them, that can modify toxic 
effects, renders toxicity studies of petroleum extremely challenging (Dennison et 
al., 2004) or unrealistic for animal studies, and unethical for human studies. An 
alternative approach is to use mathematical modeling to predict the interaction in 
various species, scenarios and doses (Haddad et al., 2010). Physiologically 
based pharmacokinetic (PBPK) modeling is a well-established tool that can be 
used to predict the pharmacokinetics of chemical compounds for different 
exposure scenarios and therefore assess the risk of exposure to these 
chemicals. PBPK models have been used for predicting kinetics in different 
species (i.e., animal or human), exposure routes, acute and chronic effects, and 
doses (Haddad et al., 2010). Haddad et al. (2007) used PBPK modeling to 
evaluate the importance of multi-route exposure (i.e., inhalation, gavage and 
dermal) in risk assessment of VOCs in the case of water contamination.  
  
In the current study, four VOCs were chosen to represent different families of 
hydrocarbons found in petroleum products. Toluene, n-hexane, cyclohexane and 
isooctane represent the aromatic hydrocarbon family, alkane class, cycloalkane 
class and branched-chain paraffin class, respectively (Chen et al., 1998). The 
toxic effects of each of these chemicals have already been documented in the 
literature. Toluene affects the central nervous system (CNS), whereas the effects 
of n-hexane are on the peripheral nervous system (Ali and Tardif, 1999; ATSDR, 
1993). Isooctane is known primarily as a nephrotoxin in male rats (Fowlie et al., 
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1987; Lock et al., 1993) and has also been shown to damage the liver in both 
male and female rats (Fowlie et al., 1987). The neurotoxicity of isooctane has 
also been reported in experimental animals (Swann et al., 1974; El-Masri et al., 
2009). Cyclohexane is a hydrocarbon that rather affects the CNS (Hissink et al., 
2009).  
 
The pharmacokinetics of each of these VOCs have already been studied 
separately using PBPK models: toluene and n-hexane by Ali and Tardif (1999); 
cyclohexane by Perico et al. (1999) and Hissink et al. (2009); and isooctane by 
El-Masri et al. (2009). These studies have evaluated the effect of exposure to 
one of these substances or a mixture of two by a single exposure route (i.e., 
inhalation, oral or dermal). However, no study has so far assessed the ability of 
the PBPK model to simulate exposure to a mixture of these hydrocarbons by 
multiple routes (i.e., inhalation + oral).  
 
The objective of this study was therefore to develop a PBPK model aimed at 
simulating the kinetics during simultaneous exposure to a mixture of toluene, n-
hexane, cyclohexane and isooctane by inhalation and gavage. 
 
Material and Methods 
 
The experimental data on the time courses of toluene, n-hexane or isooctane 
following single and multiple routes exposure have already been studied (Gagné, 
2008). Therefore, in the current study only the pharmacokinetics of cyclohexane 
was evaluated before proceeding with the construction of the multi-chemical 
PBPK models. Accordingly, this study involved the conduct of in vivo 
experiments in conjunction with PBPK modeling. During the in vivo experiments, 
groups of five male Sprague-Dawley rats were exposed to separate high dose 
and low dose of cyclohexane by single route and multiple routes of exposure 
(inhalation and gavage). Another group was exposed to a mixture of the four 
substances by multiple routes. Subsequently, PBPK models of the individual 
  
58
chemicals were interconnected using the metabolic interaction terms in order to 
simulate the kinetics of cumulative exposure to both single product and multiple 
products. Finally, the comparison of the models for single products and mixtures 
of chemicals by multiple routes of exposure was used to determine the impact of 
mixed exposure scenario on the internal dose of each substance. 
 
Chemicals 
 
Toluene 99.8%, n-hexane 99%, cyclohexane (anhydrous 99.5%) and isooctane 
(anhydrous 99.8%) were obtained from Aldrich chemicals (Milwaukee, WI). 
 
Animals 
 
Adult male Sprague-Dawley rats (240-260 g) were obtained from Charles-River 
Canada (St-Constant, Québec). They were housed in temperature-controlled 
cages in groups of two or three per cage with a 12-h light–dark cycle. A minimum 
of one week acclimatization period was provided. They were given food and 
water ad libitum until the day of experiment. On the day of experiment they were 
placed in individual cages and fasted during the experiment. 
 
Exposure scheme 
 
Inhalation exposure 
 
Groups of male Sprague-Dawley rats (n=5) were separately exposed to low and 
high concentrations of cyclohexane by inhalation (300 ppm and 1200 ppm; 2-hr) 
in a closed-atmosphere exposure system (Haddad et al., 2000). The 
concentrations were monitored using automatic injection of 0.25 ml air samples 
into a gas chromatograph (HP 5890) equipped with a flame ionization detector 
(FID). Helium was used as a carrier gas, at a rate of 5.4 ml/min.  
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Oral exposure 
 
Groups of rats (n=5) were given a single low dose (27.9 mg/kg) and high dose 
(108.9 mg/kg) of cyclohexane, diluted in Alkamuls® (10%). Tem ml of the solution 
was administrated by gavage. 
 
Multi-route exposure 
 
Multi-route exposure to cyclohexane was conducted by exposing groups of five 
rats simultaneously by inhalation and oral routes. It was performed at low dose 
(300 ppm and 27.9 mg/kg) and high dose (1200 ppm and 108.9 mg/kg). The 
inhalation exposure was performed right after oral exposure in a closed-chamber 
system for 2 hr. 
  
Mixture exposure 
 
Exposure to the mixture (toluene + n-hexane + cyclohexane + isooctane) by 
multi-route was performed only at the lower doses. Animals were exposed to the 
mixture of toluene n-hexane, cyclohexane and isooctane first by oral gavage to a 
single dose of 8.30, 5.53, 27.9 and 41.27 mg/kg, respectively, and immediately 
followed by inhalation (50, 50, 300 and 300 ppm, respectively) for two hours. 
 
Analysis of blood concentration 
 
Blood samples (25-200 µl) were collected by performing a small incision on tail 
veins of rats. The concentration of unchanged substances in blood was 
quantified using a head-space gas chromatography method (Tardif et al., 1993). 
After single oral exposure, blood samples were taken from animals at 0.5, 1, 1.5, 
2, 2.5 and 3 hr post-exposure. For the inhalation and multi-route exposure, blood 
samples were taken at 2, 2.5, 3, 3.5, 4 and 5 hr post- exposure. 
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PBPK modeling 
 
Model representation 
 
The four compartmental PBPK models to simulate the kinetics of each of the four 
VOCs consist of: liver (the metabolizing tissue), fat, richly-perfused tissues and 
slowly-perfused tissues, all connected by systemic blood circulation and gas 
exchange in the lung. The PBPK models were based on the Haddad et al. 
(2001). The new model was developed to simulate the exposure to cyclohexane 
for either inhalation or oral exposure. In the model for oral gavage and mixture 
exposure (toluene, n-hexane, cyclohexane and isooctane), the rate of chemicals 
absorbed by the gastro-intestinal tract (Aab) were added to the liver. In addition, in 
the case of exposure to the mixture (Figure 1), any interactions or inhibitions of 
the metabolism between the four chemicals were assumed to happen in the liver 
(Haddad et al., 2001). Kiab was considered as the competitive inhibition constant 
of the metabolism of the chemical a by chemical b.  
The metabolism was assumed to be a saturable process and was described by 
Vmax (maximum velocity) and Km (Michaelis-Menten affinity constant) (Krishnan 
and Peyret, 2009). The rate of change in the amount of chemical (dAt/dt) was 
estimated as: 
 
  max  ( - )
 
-dAt Cv x VQl Ca Cv
dt Cv Km
=
+
                                                                      [1] 
 
where:   
Ql: rate of blood flow through the liver 
Ca: concentration of solvent in the arterial blood 
Cv: concentration of solvent in the blood leaving the liver 
For simulating oral and multi-route exposures, the amount absorbed per unit time 
was added to the above equation as follow (Haddad et al., 2001): 
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  max  ( - ) ( )
 
- abdAt Cv x VQl Ca Cv A
dt Cv Km
= +
+
                                                        [2] 
 
where 
Aab: rate of chemical being absorbed during the oral exposure (mg/h), calculated 
as:   
 
Aab= Kx × Qt                                                                                                           [3] 
 
Where 
Kx: absorption constant of a chemical by the stomach (min-1) 
Qt: remaining quantity of chemical in the stomach (mg) 
Therefore, 
 
Qt = Q – (Aab × ta) – (Ko × ta × Aab)                                                             [4] 
 
 where  
Ko: stomach to intestine transfer constant (min¯¹) 
ta: interval of time (min) 
The rate of metabolism (ram) for each chemical after exposure to the mixture 
was calculated as for Haddad et al. (2000). For example, for toluene, ram was 
calculated as follows: 
 
= ⎡ ⎤
+ + + +⎢ ⎥⎣ ⎦
max   
(1 )
V T x CvTramT
CvH CvC CvIKmT CvT
KiHT KiCT KiIT
                                               [5] 
 
where: 
T (toluene), H (n-hexane), C (cyclohexane) and I (isooctane) 
In general: 
ramA: rate of the metabolized quantity of chemical A  
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KiAB: Competitive inhibition constant of the metabolism of the chemical A by 
chemical B 
 
Model parameterization 
 
The physiological parameters of the rat were obtained from the literature (Tardif 
et al., 1997). Physicochemical (i.e., partition coefficients) and biochemical 
parameters of toluene and n-hexane were taken from Ali and Tardif (1999), of 
cyclohexane from Hissink et al. (2009) and of isooctane from El-Masri et al. 
(2009). The PBPK model of inhalation was used to determine the values of 
Vmax= 0.005 mg/min and Km = 1 mg/l for isooctane which were then used in the 
mixture model. The metabolism was considered competitive; therefore, the 
amount of Kiab of each chemical was equal to the Km of the same chemical. The 
absorption rate by the stomach (Kx) and the rate of substance transfer from the 
stomach to the intestine (Ko) of each chemical were fitted first in the oral gavage 
model and later those values were used in the mixture PBPK model.  
 
Statistical analysis and model evaluation 
 
The statistical analyses were performed with SPSS for Windows (v15.0.0, 
Chicago, IL, USA). In order to validate the models, data-derived area under the 
blood concentration vs. time curve (AUC; mg/L x min) was calculated for every 
exposure scenario (inhalation, gavage and multi-route) and dose (low and high 
doses) and compared with those obtained using the PBPK model. The results 
were used to determine the degree of discrepancy between PBPK models and 
experimental data. 
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Results 
 
A: Cyclohexane 
 
1. Inhalation and oral exposure  
 
The PBPK model simulations of inhalation kinetics of cyclohexane was in 
agreement with the experimental data and estimated well the maximum blood 
concentrations (Cmax) for both low exposure (300 ppm; 2 hr) and high exposure 
(1200 ppm; 2 hr) groups (Figure 2A). However, it seemed that after reaching the 
Cmax, the model underestimated the experimental data for both inhalation and 
oral exposure conditions.   
Results from the cyclohexane PBPK model after a single low dose (27.9 mg/kg) 
and high dose (108.9 mg/kg) via oral route concurred with the experimental data 
(Figure 2B). The values of Kx and Ko obtained by fitting to the model were 0.5 
min-1 and 0.3 min-1, respectively. The area under the curve (AUC) from 0.5 hr to 
5 hr following low oral dose was 21.4 mg/L.min for the PBPK model vs 24.6 
mg/L.min for the experimental data. For high oral dose of 108.9 mg/kg, the AUCs 
were 308.3 mg/L.min and 112.2 mg/L.min, respectively, for the PBPK model and 
experimental data.  
 
2. Multi-route exposure 
 
Although the PBPK model of cyclohexane predicted the Cmax for both low dose 
(27.9 mg/kg and 300 ppm) and high dose (108.9 mg/kg and 1200 ppm), after this 
point, model predictions underestimated the experimental data. The model-
simulated AUC for low dose multi-route exposure to cyclohexane was 16.63 
mg/l.min whereas the data-derived AUC was 112.04 mg/l.min. However, no 
modification of the physiological and physiochemical parameters of the PBPK 
model of cyclohexane was performed to improve the fit, because cyclohexane 
did not significantly interfere or alter the kinetics of other substances in the 
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mixture. Further work to improve the predictive capacity of the cyclohexane 
model was beyond the goals of the present study. 
 
B: Mixture/multi-route exposure  
 
The capacity of the PBPK model to simulate multi-route exposure to a mixture in 
rats was evaluated by comparing the unchanged blood concentrations of each 
chemical obtained with the PBPK model to the respective experimental data. 
Toluene, n-hexane, and isooctane showed a reasonable fit (Figures 3A to 3C). 
However, in the case of cyclohexane, only the Cmax could fit (Figure 3D). The 
AUC (2-6 hr) of cyclohexane based on the experimental data (159.58 mg/l.min) 
differed from simulated value (19.55 mg/l.min), by the same factor (~7) during 
multiple chemicals and simple chemical exposures. Table 2 shows comparisons 
between the AUCs of the PBPK model for each substance and experimental data 
after exposure to the mixture by multiple routes (low doses).  
 
Another important result is the demonstration of the effects of mixture exposure 
by multi-route on the internal dose for each chemical compared to the effects 
produced by single product multi-route exposures. The results show that blood 
concentration of toluene and hexane increases during mixture multi-route 
exposure compared to the single multi-route exposure. However, the extent of 
change in kinetics for isooctane was not marked. For cyclohexane, examining the 
experimental data of exposure to either single product or mixture, no change was 
observed. 
 
C: Sensitivity analysis 
 
Results for cylcohexane showed that whenever inhalation exposure was involved 
(i.e., simple inhalation, multiple routes), the existing PBPK model did not 
correspond well with the experimental data. Therefore, a sensitivity test was 
performed (i.e., change of each parameter by 1% while the rest was kept 
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constant) (Table 3). These analyses showed that the blood: air partition 
coefficient (Pb) was the most sensitive parameter. By changing Pb from 1.3 
(Hissink et al. 2009) to 7, the model correlated well with the experimental data in 
all three cases (i.e., cyclohexane inhalation, multi-route exposure to cyclohexane 
alone, and multi-route exposure to a mixture including cyclohexane) (Figure 7A-
D). but due to (i) lack of a mechanistic basis to change Pb of cyclohexane and (ii) 
its inability to alter kinetics of other hydrocarbons evaluated in this study, no 
change to the cyclohexane model or its parameters were attempted. 
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Discussion 
 
This is the first study to show the capacity of a PBPK model to simulate the 
exposure to a mixture of hydrocarbons simultaneously by inhalation and oral 
gavage. Although dermal route was not considered in the multi-route 
experiments, it did not seem to have an important impact on the outcome since 
at the chosen doses it was not one of the principal absorption routes (Table 1). In 
fact, preliminary experiments on rats showed that under the experimental 
conditions of this study, dermal route did not significantly contribute to the 
absorption of any of the four substances. 
 
The PBPK models, as well as the experimental data, show that exposure of rats 
to the mixture compared to the single chemical (both by multi-route exposures) 
results in the inhibition of the metabolism of toluene and n-hexane but no 
difference in kinetics of isooctane. The PBPK model of cyclohexane could not fit 
the experimental data (except for Cmax). However, experimental data from 
cyclohexane did not show significant impact or interaction towards the other 
components of the mixture. 
 
A brief summary of the metabolism pathway for each of the substances can help 
a better understanding of the possible interactions between them. The 
cytochromes (CYP) mammalian hepatics microsomal are responsible for the 
biotransformation of a large number of xenobiotic substances. CYP enzymes 
need two electrons and two protons to catalyze the oxidation of the substance. 
Therefore after the substance binds to CYP, the first electron is transferred by 
NADPH-CYP450 reductase (CPR). However, the second electron can be 
delivered from either CPR or CYTb5 (Denisov et al. 2005). Toluene is 
metabolized by CYP2E1 and CYP2B1/B2 in the liver (Nakajima et al. 1997).  
  
n-Hexane is also mainly metabolized by CYP2B1 in the liver (Nakajima et al. 
1997; Fabioano et al. 2010). Therefore toluene and n-hexane are likely to 
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compete for the same cytochrome CYP2B1. In fact, it has been shown that 
respiratory exposure to the mixture of toluene and n-hexane results in a reduced 
toxic effect compared to an exposure to n-hexane alone (Takeuchi et al. 1981). 
Takeuchi et al. (1981) showed that exposure to a mixture of 1000 ppm of toluene 
and 1000 ppm n-hexane in rats, 12 hours a day for 16 weeks, resulted in a 
reduction of the peripheral neurotoxic effects caused by an exposure to 1000 
ppm of n-hexane alone. The interaction in the metabolism has also been shown 
at lower doses and shorter exposure durations.  Exposure to the mixture of 300 
ppm toluene and 100 ppm n-hexane, 12 hours a day for four weeks, showed a 
reduction by up to 75% of the urinary 2,5-hexanedione (n-hexane metabolite) 
and a 28% reduction of the urinary hippuric acid (toluene metabolite) (Ali and 
Tardif, 1999).  
 
Consistent with the available information, the current study also shows inhibition 
of the metabolism of both chemicals regardless of the presence of two other 
chemicals (isooctane and cyclohexane) and multi-route exposure (Figures 4A-B 
and 5A-B). However, the effects of cyclohexane and isooctane cannot be 
underestimated. Cyclohexane is metabolized into cyclohexanol in the liver by 
CYP2B4 (Zhang et al. 2007). Evidence suggests that cyclohexanol induces 
CYP2E1, CYP2B1/B2 (Espinosa-Aguirre et al. 1997). Nonetheless, the 
experimental data in this study showed that metabolism of cyclohexane after two 
hours of exposure in both simple and multi-route exposure was not considerable. 
Suspecting that cyclohexane could not have had an important effect on the 
inhibition of the metabolism of either n-hexane or toluene. In order to prove that, 
the PBPK model of exposure to the mixture of four substances was compared to 
exposure to a mixture without cyclohexane. The result showed that after 
removing cyclohexane from the mixture the metabolism rate and kinetics of both 
n-hexane and toluene were unchanged (Figures 4A-B).  
 
Furthermore, in order to show the importance of isooctane in the mixture, the 
PBPK model was adapted to simulate the exposure to a mixture without it. By 
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comparing the PBPK models, a slight change in the internal dose of toluene was 
noticed (Figure 5A). These results, together with evidence from toluene and n-
hexane mixture studies (Ali and Tardif, 1999), suggest that the inhibition of 
toluene after a cumulative exposure to a mixture is not caused by cyclohexane or 
isooctane, but by n-hexane. These assertions are supported by the sensitivity 
analyses that showed that changes in the input parameters of cyclohexane or 
isooctane have no important effect on either toluene or n-hexane (Table 4).  
 
The PBPK model adapted in this study to cyclohexane could reasonably fit 
experimental data from oral gavage but not experiments related to inhalation 
exposures (i.e., simple and multi-route). The sensitivity test showed that among 
all the parameters used in the PBPK model of cyclohexane, blood:air partition 
coefficient is the most sensitive one (Table 3).  In fact, by changing this 
parameter from 1.3 to 7, the PBPK model could fit the experimental data each 
time (Figures 7A-D). Interestingly, this change made no difference in the PBPK 
simulation of the kinetics of other chemicals in the mixture (i.e., toluene, n-
hexane and isooctane).  
 
In a different attempt to show the reliability of the adapted PBPK model of 
cyclohexane, the experimental data from a recent study (Hissink al. 2009) were 
compared to the model. In fact, our PBPK model could fit the data from the other 
study (Figure 6). The difference between the two studies was in exposure times 
(2 hr in our study vs 8 hr in the study by Hissink et al. (2009)). In fact other 
studies have shown that, because of the chair conformation of cyclohexane, the 
activation energy required to break the C-H bond is relatively high (418 Kj.mole-1) 
and this would explain the slow metabolism rate of cyclohexane in mammalians 
compared to bacterial CYT P450 system (Lewis, 2001). Interestingly, in an in-
vitro experiment, Zhang et al. (2007) could determine the possibility of a 
competition on the binding site of CYP2B4 between CPR and CYTb5. They 
reported that increase of the molar ratio of CYTb5 in a 3-substrate experiment 
(i.e., CYP2B4 : CPR : CYTb5 ; 1 : 1 < 1) will cause a decrease of oxidation of 
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cyclohexane. The authors explained this outcome by replacement of CPR by 
CYTb5 (due to competition between them), which would result in the inhibition of 
the first step in the catalytic cycle of oxidation of cyclohexane. 
 
Isooctane on the other hand, demonstrated no difference in metabolism between 
aggregate and cumulative exposures, as shown both by the PBPK model and 
experimental data. There is no study to support the effect of isooctane on the 
metabolism of other substances.  
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Conclusion 
 
The importance of exposure to a mixture by multiple routes has been widely 
accepted by scientists and governmental regulatory agencies. However, it is very 
difficult to consider the many possible combinations of chemicals and exposure 
routes in the risk assessment process. Our study shows, for the first time, that 
PBPK models are reliable tools to overcome, at least in part, the challenges 
involved in studying multi-route mixture exposure. It also demonstrates that there 
are not necessarily chemical interactions between all VOCs. Therefore, the study 
of mixture and possible interactions between substances while considering the 
multiple routes of exposure is important in regulatory evaluations. This study 
shows that PBPK models can be used to assess such complex scenarios in rats. 
Further studies are required to elucidate the possibility of extrapolating these 
animal models to humans, which could then be used in mixture risk assessment. 
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Table 1: Characterizations of toluene, n-hexane, cyclohexane and isooctane 
 
 Toluene n-Hexane Cyclohexane Isooctane 
 
TLV®* 1    
(PPM)  
 
50 
 
50 
 
300 
 
300 
 
Principal 
toxicity 
 
Central Nervous 
System (CNS) 13 
Peripheral Nervous 
System 11 
 
 
CNS 9 
 
 
nephrotoxin in male rat 8 
  respiratory arrest at  
concentration>32000ppm
14    
 
Route-
specific 
absorption 
efficiency  
 
 
 Short exposure:        
Respiratory (85-90) 
Long exposure> 
1h:  Respiratory & 
oral (50/50) 7    
Dermal exposure 
1% (vapor), less in 
liquid phase 7 
Principal route: 
Respiratory tract. 
At Higher dose  
gastrointestinal 
tract and skin 3   
Dermal absorption; 
Not significant (0.82 
µg.cm²/hr)3 
  
Principal route: 
Respiratory and 
digestive system: 
23% 10 
Dermal Route: 
23% (vapor), 5% 
liquid phase10 
  
 oral exposure; 
 to 500mg/kg: 95% 6  
   respiratory exposure; 
 to 0.79 ppm (low): 7% 
  385 ppm (high): 12%5 
 
Metabolic 
product 
 
Hippuric acid 2 
  
 
2,5-hexanedione 
(HD)11 
 
Cyclohexanol 12 
 
 2,4,4-trimethyl-2-pentanol 
4  
  
 
*    (TLV) ®: Threshold limit value 
  **   Alveolar retention: difference between inhaled and alveolar concentrations of volatile 
1. ACGIH (1999) 
2. ATSDR (1993) 
3. Bonnard et al. (2008) 
4. Charbonneau et al. (1987) 
5. Dahl (1989) 
6. U.S. EPA (2007) 
7. Faust (1994) 
8. Lock et al. (1993) 
9. Malley et al. (2000) 
10. Mutti et al. (1981) 
11. Ali and Tardif, (1999) 
12. Perbellini et al. (1981) 
13. Rosenberg et al. (1988) 
14. Swann et al. (1974) 
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Table 2. Comparison of the area under the blood concentration (AUCs) vs time 
course mg/l.min obtained from PBPK model and experimental data after 
exposure to mixture by multiple routes (inhalation and oral) in rats. 
 
 
  
Chemical 
 
AUC (mg/L.min) 
(120- 360 min) 
 
PBPK 
 
Experimental data 
Toluene 121.73 157.25 
 
n-Hexane 21.91 18.77 
 
Cyclohexane 19.55 159.58 
 
Isooctane 170.54 176.54 
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Table 3: Normalized sensitivity coefficients for input parameters of the PBPK 
model for cyclohexane. (Pbc, Plc, Pfc, Prc, Psc, Vmaxc and Kmc refer to blood: 
air partition coefficient, liver : air partition coefficient, richly-perfused : air partition 
coefficient and slowly-perfused : air partition coefficient, maximal velocity of 
metabolism and Michaelis-Menten constant).  
 
Parameters Cyclohexane
Pbc -0.831
Plc 0.000
Pfc 0.256
Prc -0.075
Psc -0.416
Vmaxc 0.115
Kmc -0.049
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Table 4: Normalized sensitivity coefficients for input parameters of cyclohexane 
(c) and isooctane (i) in the mixture PBPK model. (Pb, Pl, Pf, Pr, Ps, Vmax, Km, 
Ki, Ko, and Kx refer to blood : air partition coefficient, liver : air partition 
coefficient, richly-perfused : air partition coefficient, slowly-perfused : air partition 
coefficient, maximal velocity of metabolism, Michaelis-Menten constant, inhibition 
constant, absorption rate constant for stomach and stomach to intestine transfer 
rate). 
 
          
Paremeters   toluene  n-hexane cyclohexane isooctane  
     
Plc -0.008 -0.004 -0.005 -0.006 
Pfc 0.008 0.000 0.320 0.003 
Prc -0.002 0.000 -0.076 -0.001 
Psc 0.000 0.000 0.000 0.000 
Pbc -0.045 -0.013 -1.038 -0.033 
Vmaxc 0.044 
 
0.013 0.148 0.031 
Kmc -0.044 -0.013 -0.142 -0.032 
Kic 0.071 0.021 0.010 0.051 
Koc -0.003 0.000 -0.056 -0.003 
Kxc 0.005 0.000 0.061 0.003 
         
Pli -0.005   0.000 0.000 -0.015 
Pfi 0.005 0.000 0.005 0.062 
Pri 0.000 0.000 0.000 -0.008 
Psi -0.008 -0.004 0.127 -0.060 
Pbi -0.022 -0.009 0.259 -0.060 
Vmaxi 0.000         0.000 
  
0.000 
     
0.000 
Kmi -0.007 -0.004 0.051 -0.026 
Kii 0.180 0.060 0.051 0.118 
Koi 0.000 0.000 0.000 0.000 
Kxi 0.000 0.000 0.000 0.000 
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List of Figures:  
 
Figure 1: PBPK model of multi-route exposure to the mixture of four chemicals 
(tolune (t), n-hexane (h), cyclohexane(c) and isooctane (i)) by inhalation and oral 
gavage. The toxicokinetic interactions among the four substances occur in the 
liver. RAM; rate of the metabolism of each substance, arterial blood (Arterial), 
venous blood (Venous), richly-perfused tissues; RPT, poorly-perfused tissues 
(PPT), GI tract; gastrointestinal tract.  
 
Figure 2A: Comparison of PBPK model simulations (solid lines) with the 
experimental data (symbols) of inhalation exposure to 300 ppm or 1200 ppm (2 
hr) of cyclohexane in rats. 
 
Figure 2B: Comparison of the PBPK model simulations (solid lines) to the 
experimental data (symbols) of single oral gavage exposure to 27.9 mg/kg 108.9 
mg/kg of cyclohexane in rats. 
 
Figure 2C: Comparison of the PBPK model simulations (solid lines) with the 
experimental data (symbols) of aggregate exposure to 27.9 mg/kg + 300 ppm or 
108.9 mg/kg + 1200 ppm of cyclohexane (single oral dose followed by 2 hr 
inhalation). 
 
Figure 3A: PBPK model simulations (solid lines) and experimental data on 
venous blood concentration in rats exposed to toluene alone (♦) or as a mixture 
(■) by multiple routes. 
 
Figure 3B: PBPK model simulations (solid lines) and experimental data on 
venous blood concentration in rats exposed to n-hexane alone (♦) or as a mixture 
(■) by multiple routes. 
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Figure 3C: PBPK model simulations (solid lines) and experimental data on 
venous blood concentration in rats exposed to isooctane alone (♦) or as a 
mixture (■) by multiple routes.  
 
Figure 3D: PBPK models simulation (solid lines) and experimental data on 
venous blood concentration in rats exposed to cyclohexane alone (♦) or as a 
mixture (■) by multiple routes.  
 
Figure 4A: Comparison of the simulations of PBPK models of toluene in a 
mixture in presence or absence of cyclohexane. Gray line indicates simulation 
without cyclohexane. 
 
Figure 4B: Comparison of the simulations of PBPK models of n-hexane in a 
mixture in presence or absence of cyclohexane. Gray line indicates simulation 
without cyclohexane. 
 
Figure 5A: Comparison of the simulations of PBPK model of toluene in a mixture 
in presence or absence of isooctane. Gray line indicates simulation without 
isooctane. 
 
Figure 5B: Comparison of the simulations of PBPK model of n-hexane in a 
mixture in presence or absence of isooctane. Gray line indicates simulation 
without isooctane. 
 
Figure 6: PBPK model simulations of the kinetics of cyclohexane and comparison 
with the experimental data (points) from Hissink et al. (2009) (400 ppm and 2000 
ppm). 
 
Figure 7A: PBPK model simulations of the inhalation kinetics of cyclohexane in 
rats to 300 ppm and 1200 ppm. To obtain these simulations, blood: air partition 
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coefficient (Pb) was set to 7 instead of 1.3 based on the result of sensitivity 
analysis.  
 
Figure 7B: PBPK model simulations of the oral kinetics of cyclohexane in rats 
administrated 27.9 mg/kg and 108.9 mg/kg. To obtain these simulations, blood: 
air partition coefficient (Pb) was set to 7 instead of 1.3 based on the result of 
sensitivity analysis. 
  
Figure 7C: PBPK model simulations of multi-route exposure to cyclohexane. 
Blood: air partition coefficient (Pb) was set to 7 instead of 1.3 based on the result 
of sensitivity analysis (High dose (1200 ppm + 108.9 mg/kg); low dose (300 ppm 
+ 27.9 mg/kg)). 
 
Figure 7D: impact of the blood : air partition coefficient (pb) on the simulations of  
PBPK model of cyclohexane kinetics during multi-route exposure (300 ppm + 27.9 
mg/kg). 
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Figure 1 
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Figure 2B  
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Figure 2C  
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Figure 3A  
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Figure 3B 
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Figure 3C  
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Figure 3D 
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Figure 4A 
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Figure 4B 
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Figure 5A 
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Figure 5B 
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Figure 6 
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Figure 7A 
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Figure 7B 
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Figure 7C 
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Figure 7D 
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Discussion 
 
In the process of deriving the guideline values of chemical contaminants in 
drinking water, there has not been any attempt to take into account mixed 
exposures and multiple routes of exposure. The main reason is that the number 
of experiments using individual and mixture of chemicals by single and multiple 
routes of exposure required would be enormous, and that would be impractical, 
expensive and unethical in humans. The present study showed the capacity of 
PBPK models to support the interpretation of results from limited but focused 
experiments for multi-route and multi-chemical exposures.  
 
To accomplish this objective, four VOCs (toluene, n-hexane, cyclohexane and 
isooctane), present in the petroleum products that have great potential to 
contaminate the drinking water, were chosen. PBPK models of toluene for both 
single and multi-routes of exposure were already available (Gagné, 2008). 
Therefore, PBPK models of n-hexane, isooctane (first article) and isooctane 
(second article) were developed to simulate separate chemical exposure by both 
single and multiple routes (inhalation and oral) in rats. The models were 
compared with the experimental data collected for the same scenarios of 
exposure in rats. The results showed the capacity of the PBPK models to 
simulate the kinetics of individual chemicals for simple or multiple routes of 
exposure. Then, the PBPK models were applied to analyze simultaneous 
exposure to the mixture of toluene, n-hexane, cyclohexane and isooctane by 
multiple routes (second article). Experimental data and PBPK modeling showed 
that after a 2-hr exposure to lower doses, there were interactions between 
toluene and n-hexane. These interactions result from a likely inhibition of the 
metabolism of n-hexane and toluene due to their competition for CYP2B1 
(Nakajima et al. 1997; Fabioano et al. 2010), leading to higher blood 
concentrations of the parental compounds. However, no change in the 
metabolism of isooctane was observed. The role of cyclohexane for the possible 
interaction with other chemicals was omitted, as supported by the sensitivity 
  
107
analyses. This emphasizes the fact that one or more of the components of a 
mixture may not interact with other components, and may just act independently. 
 
In exploring the results obtained in the present study, the logical next step would 
be to extrapolate the PBPK model to humans and use it in the mixture risk 
assessment process. The advantage of PBPK modeling approaches is the ability 
to conduct calculations for untested/selected exposure scenarios. In this regard, 
the PBPK model of multiple routes of exposure to a mixture of four chemicals 
was compared to the result of the PBPK model of individual chemicals. The skin 
compartment was added to the mixture PBPK model described in Article 2 of this 
thesis. The integrated multiple route PBPK model was then used to simulate a 
subject (body weight: 70 kg, body surface area: 18000 cm2) taking a 10-min 
shower (exposure to VOCs through dermal and inhalation) and spending the rest 
of the day indoors and consuming a total of 1.5 L of drinking water (as per Health 
Canada).  For conducting simulations, in addition to the physiological parameters 
of humans from Haddad et al. (2007), chemical-specific parameters (i.e., partition 
coefficients and biochemical) were obtained from Ali and Tardif (1999; toluene 
and n-hexane), Hissink et al. (2009; cyclohexane) and El-Masri et al. (2009; 
isooctane). Parameters such as Kp (dermal permeability constant to a chemical), 
Psw (skin: water partition coefficient) and Psa (skin: air partition coefficient) were 
calculated using the following formulas:   
 
Log Kp = - 0.812 - 0.00104 x MW + 0.616 x logKow                         (Bogen, 1994) 
 
Psw: 1.2771 + 0.1208 Kow                                                        (Robert et al. 1975) 
 
Psa: Psw / Kaw 
 
Kow: Koa / Kwa 
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Where: 
Koa (oil: air partition coefficient): toluene, 1539; n-hexane, 157; cyclohexane, 331 
and isooctane, 366) are from Meulenberg and Vijverberg (2000). 
Kwa (saline: air partition coefficient): toluene, 2.19; n-hexane, 0.015; 
cyclohexane, 0.15 and isooctane, 0.0014 are from Meulenberg and Vijverberg 
(2000). 
 
Total amounts absorbed during multiple routes of exposure was compared to the 
quantity absorbed via the oral route (or 1.5 L) to derive the liter equivalent (L-eq) 
for each substance as per Krishnan and Carrier (2008): 
 
L-eq multiple routes= quantity of chemical absorbed by multiple routes ( g / L)
quantity absorbed by oral route ( g / L)
µ
µ
  
  
L-eq total = 1.5 + (1.5 x L-eq of multiple routes) 
 
Therefore, the guideline value would equal (TDI x BW X SAF): 
L-eq total
 
The following Tables 3 and 4 present L-eq obtained using the PBPK models 
developed in the present study and scaled to humans.  
 
Table 3: Comparison of the L-eq of each substance resulting from multi-routes 
exposure to mixture between different concentrations: 100 µg/L and 1 µg/L. 
 
          L-eq of Mixture 
             100 µg/L 
         L-eq of Mixture 
1 µg/L 
Toluene 4.93 4.55 
n-Hexane 2.20 2.18 
Cyclohexane 3.89 3.47 
Isooctane 1.62 1.62 
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Table 4: Comparison of the L-eq of each substance resulting from multi-routes 
exposure of separate substances between different concentrations: 100 µg/L and 
1 µg/L. 
 
 L-eq of single substance 
100 µg/L 
L-eq of single substance 
1 µg/L 
Toluene 3.77 3.77 
n-Hexane 2.13 2.13 
Cyclohexane 4.46 4.46 
Isooctane 1.61 1.61 
 
 
The use of PBPK models indicate that under the single chemical exposure 
situations, the calculated L-eq is similar for various water concentrations that 
essentially stay in the ‘linear’ range of metabolic enzymes (Table 4).  However, in 
case of mixture exposure via multiple routes, as it was expected, there is an 
increase in the amount of L-eqs of toluene and n-hexane, more likely as a result 
of competition among chemicals (Table 3).  
 
The PBPK models can be used to simulate various scenarios to determine the 
combination of water concentrations of VOCs that would or not result in 
significant metabolic inhibition among them. Using this predictive simulation 
approach, we can then potentially improve the standard-setting process for 
drinking water chemicals that occur as mixtures. 
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